parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in cytotrophoblasts	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 378	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 10309

EFEMP1 in astrocytes, braak-0.02 (p 0.964) → +0.15 (p 0.699)receipt 10314
EFEMP1 in dopamine neurons, braak+0.34 (p 0.375) → +0.57 (p 0.109)receipt 10315

receipt 10315: EFEMP1 in dopamine neurons, braak

power: full sample +0.29 (p 0.250, n 18), 95% CI -0.21 to +0.66. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.26 (p 0.302, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.19 (p 0.450, n 18). could be the mix.
skeptic: leave-one-out range +0.20 to +0.44, sign flips 0; without severely affected donors +0.29 (p 0.250, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EFEMP1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 10314: EFEMP1 in astrocytes, braak

power: full sample +0.09 (p 0.715, n 18), 95% CI -0.39 to +0.54. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.12 (p 0.646, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.28 (p 0.265, n 18). could be the mix.
skeptic: leave-one-out range -0.01 to +0.21, sign flips 2; without severely affected donors +0.09 (p 0.715, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EFEMP1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts